APH02174 as a highly selective and orally bioavailable IRAK4 PROTAC degrader in the treatment of inflammatory diseases mediated by IRAK4 signaling. APH02174 demonstrated significant therapeutic efficacy by effectively alleviating imiquimod-induced psoriasis-like skin inflammation and antiarthritic activity in mouse models.
MedKoo Cat#: 129049
Name: APH02174
CAS#: N/A
Chemical Formula: C49H55N7O8
Exact Mass: 869.4100
Molecular Weight: 870.02
Elemental Analysis: C, 67.65; H, 6.37; N, 11.27; O, 14.71
The following data is based on the product molecular weight 870.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Wu XW, Chen ZM, Gao C, Liu XL, Wang H, Chen HJ, Liu SH, Liu JZ, Li HX, Yang D, Yang WQ, An LK. Discovery of APH02174 as a Highly Selective and Orally Bioavailable IRAK4 Degrader for the Treatment of Inflammatory Diseases. J Med Chem. 2025 Jun 17. doi: 10.1021/acs.jmedchem.5c00711. Epub ahead of print. PMID: 40526114.
